Rio Tinto (ADR) vs GeneDx Holdings Corp — how do they compare? Rio Tinto (ADR) trades at $102.57 (market cap $170.47B), while GeneDx Holdings Corp trades at $86.53 (market cap $2.56B). The key difference: Rio Tinto (ADR) is far larger — about 66.6× GeneDx Holdings Corp's market cap, and Rio Tinto (ADR) pays a 4.48% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| RIO | WGS | |
|---|---|---|
Market Cap | $170.47B | $2.56B |
Sector | Industrials | Technology |
52-Week High | $112.04 | $167.51 |
52-Week Low | $61.98 | $34.51 |
Enterprise Value | $183.82B | $2.60B |
Dividend Yield | 4.48% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.
Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.
Trailing returns across standard periods
Latest headlines on both assets
Rio Tinto is a global mining company that produces metals and minerals including iron ore, aluminium, copper, and lithium. Its operations supply materials used in construction, manufacturing, transportation, and energy systems.
Read more on RIO →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →